Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The first-in-human, open-label, single-dose, exploratory clinical trial evaluating the biodistribution and safety of 203Pb-AR-RMX in patients with somatostatin receptor positive neuroendocrine tumors.

Trial Profile

The first-in-human, open-label, single-dose, exploratory clinical trial evaluating the biodistribution and safety of 203Pb-AR-RMX in patients with somatostatin receptor positive neuroendocrine tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 23 Jan 2018

At a glance

  • Drugs 203-Pb-AR-RMX (Primary)
  • Indications Neuroendocrine tumours
  • Focus Diagnostic use; First in man
  • Most Recent Events

    • 23 Jan 2018 According to an Orano Med media release, AREVA Med changed its name to Orano Med.
    • 10 Jul 2017 New trial record
    • 22 Jun 2017 According to a RadioMedix media release, this exploratory trial was completed in May 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top